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Abstract— 8-Arylinosines have been scarcely studied for therapeutic purposes, probably due to 
difficulties in their synthesis. The recently described direct arylation reaction at position 8 of purine 
nucleosides has been employed to synthesize a series of 8-aryl and 8-pyridylinosines. These 
compounds have been studied for hydrolytic stability and subjected to biological evaluation. Three 
compounds have shown a pronounced specific inhibition of P. falciparum-encoded purine 
nucleoside phosphorylase, an important target for antimalarial chemotherapy.  
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1. – Introduction. 
C-8 Arylpurine nucleosides are interesting chemical entities due to their potential as therapeutic 
agents and as tools for biomolecular applications, as recently reviewed [1].  These compounds are 
mostly synthesized by Suzuki or Stille cross-coupling processes starting from the corresponding 8-
bromonucleosides. More recently a direct arylation reaction at position 8 of purine nucleosides has 
been described by two independent groups [2, 3] mediated by a Pd-Cu catalyst system with aryl 
iodides using an appropriate base. This reaction has been applied to the unprotected nucleosides to 
obtain C-8 aryl nucleosides in a single reaction step [2, 3]. Moreover the reaction works well with 
either electron-donating or electron-withdrawing aryl iodides allowing the introduction of different 
aryl substituents. This interesting synthetic procedure has been applied mostly to adenosine 
derivatives [2, 3]  and has been scarcely explored  for guanosine and inosine [4].  
Our research group has been involved in the synthesis and the biological evaluation of inosine 
nucleosides, and we have reported their behaviour as inhibitors of nucleoside-processing enzymes 
[5] as well as their capacity to inhibit new blood vessel formation [6-8]. Moreover it is well-known 
that inosine derivatives are interesting entities for evaluation against purine nucleoside 
phosphorylase, a key enzyme in the purine salvage pathway of humans and different pathogens [9, 
10]. Among the latest, PNP from Plasmodium falciparum is probably the best studied target [11-
14]. Thus, the recently described direct arylation reaction sounds appealing to our interests to access 
C-8 aryl inosine nucleosides (Figure 1) and to explore their biological potential as 
chemotherapeutics. 
So our initial approach was to apply the reaction conditions set up by Fairlamb for adenosines [4] 
and to introduce a variety of differently substituted aryl groups at position 8 of inosine. However, 
our attempts to apply this described procedure to inosine did not meet a successful outcome. Only a 
very low conversion to the desired 8-aryl compound was detected accompanied by serious 
difficulties to isolate a pure compound for biological testing. This different behaviour of inosine 
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compared to adenosine could be partially ascribed to low solubility, a problem already described in 
other synthetic approaches. Therefore, our working strategy has been to increase the solubility of 
inosine by protection of the nucleoside OHs, prior to performing the arylation reaction. Very 
recently other authors have also used a protection/deprotection procedure while performing C-C 
cross coupling reactions in inosines [15]. The reported examples in adenosine require, in general, 
long reaction times, typically overnight [4] or even up to 60 hours [2]. We have found that 
application of microwave-assisted synthesis has allowed performing the reaction on protected 
inosine in one hour. The synthesized inosines have been evaluated against purine nucleoside 
phosphorylases of different origins. In parallel their antiviral activity has also been determined.  
 
2.- Results and discussion. 
2.1. Chemistry. 
The described procedures for the direct C-8 arylation of adenosines [2-4] require the participation of 
an appropriate base (mostly Cs2CO3 and/or piperidine) whose role has been well-studied by 
Fairlamb and co. [3, 4]. Therefore the protection of the sugar OHs had to be performed with a basic-
stable protecting group, and this made us to consider the commercially available 2´,3´-O-
isopropylideninosine (1) as a convenient starting material. Reaction of 1 with 4-iodoanisole in the 
presence of Cs2CO3 (2.5 eq), CuI (3.0 eq), piperidine (0.4 eq), Pd(OAc)2 (0.05 eq) and 4-
iodoanisole (2.0 eq) in dry and degassed DMF (5 mL/mmol)  in a vacuum-dried Schlenk tube at 80 
°C overnight afforded the C-8 arylated compound (2) in approximately 22% yield (Scheme 1). 
HPLC-MS analysis of the reaction mixture indicated that the only accompanying nucleoside 
product was the starting material. Attempts to increase the yield by prolonging the reaction time 
and/or by increasing the quantities of the reactives were almost unsuccessful; only increasing the 
temperature slightly improved the conversion. At this stage, the use of microwave (MW) heating 
was considered. Indeed Alami [16] had previously successfully applied microwave irradiation for 
the direct C-8 arylation of non-ribose adenines employing high temperatures (160 °C). However 
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when Farirlamb´s group applied these conditions to the arylation reaction of 2´-deoxyadenosine [4], 
extensive breaking of the glycosidic bond was detected ascribed to the sensitivity of this bond to 
such high temperatures. Based on the higher stability of ribonucleosides compared to their 2´-
deoxynucleoside analogues, we decided to assay microwave-irradiation for the synthesis of 2 
applying lower temperatures. We were glad to see that the microwaved-reaction of 1 with 4-
iodoanisole in DMF in the presence of Cs2CO3, CuI, Pd(OAc)2 and piperidine at 120 °C for 1 h 
showed a clear conversion to the coupling product 2 with no detection of glycosidic bond cleavage.  
However, the work-up procedure was found problematic. Removal of the metal salts was partially 
performed by filtration, but attempts to completely eliminate these salts by acid treatment as 
described by other authors led to extensive decomposition through breakage of the glycosidic bond. 
In our hands, the solid isolated after filtration and subsequent chromatography was deeply coloured, 
probably indicating the concomitant presence of some metal salts. We were seriously concerned 
about the coexistence of metal containing by-products that might be a source of influencing and 
misinterpretation of the biological results. Indeed the use of copper salts, extensively applied in 
click chemistry, is being reconsidered when applied to the synthesis of compounds meant for 
biological screening, since such salts may have a clear impact on cellular events masking the real 
properties of the compounds [17-19]. Therefore, to assure the removal of any metal contaminants, 
the compound obtained after chromatography was extensively treated with Quadrasil MP in DMF 
overnight. Filtration of the resin afforded the 8-arylnucleoside 2 as a white solid in 52% overall 
yield.  
The next step involved the removal of the isopropylidene group but the acid conditions required 
provoked partial breaking of the glycosidic bond generating a variable proportion of 8-(4-
methoxyphenyl)hypoxanthine. The cleanest deprotection was observed by time-controlled treatment 
with a mixture of TFA/dioxane/H2O (4:1:1) at rt, and quenching with NH4HCO3. In this way, 
compound 3 was isolated in 98% yield.  
6 
 
The pathway step-up for the synthesis of 3 as a model compound was applied to the reaction of 1 
with different aryl iodides. The results obtained are shown in Scheme 2. Thus reaction of 2´,3´-O-
isopropylideneinosine (1) with a variety of aryl iodides (3-iodoanisole, 4-iodotoluene, 4(3)-
trifluoromethylphenyl iodides) under microwave conditions (120 °C, 1h) using Cs2CO3, CuI, 
Pd(OAc)2 and piperidine afforded the 8-arylinosines (4-7) in good yields. No significant differences 
were observed when employing electrondonating or electronwithdrawing groups at the aryl moiety, 
in agreement with that reported by other authors [4, 20]. The reaction also took place when an aryl 
bromide was used (i.e., 4-bromoanisole) but the yield was significantly lower than that obtained 
with the corresponding aryl iodide. In all cases, Quadrasil MP treatment was crucial to obtain a pure 
compound. Removal of the isopropylidene group in compounds 4-7 afforded the deprotected 
ribonucleosides 8-11 in good to excellent yields.  
Based on these results, the reaction was extended to the synthesis of 4-pyridyl or 3-pyridyl 8-
substituted inosines (Scheme 3). Thus reaction of 2´,3´-O-isopropylideneinosine (1) with 4-
iodopyridine or 3-iodopyridine afforded the corresponding coupling products at position 8, 12 and 
13, in 55 and 54% yields, respectively. Deprotection of the isopropylidene group provided the 8-
pyridylinosines 14 and 15, in 78 and 69% yields, respectively.  
 
2.2 Hydrolitic stability studies.  
It has been described that 8-substituted purine nucleosides are more sensitive to acidic conditions 
than their non-substituted analogues [1, 21] and indeed we have experienced serious difficulties to 
remove the isopropylidene group by acid treatment without affecting the glycosidic bond.  In this 
scenario, we considered relevant to determine the hydrolytic stability of the synthesised 8-
substituted inosines at different pH values. The compounds were incubated at 37 °C in buffered 
solutions at three different pHs (1.2, 5.0 and 7.4) and the evolution was followed by HPLC at 
different time points (0, 1h, 4h and 24h). Compounds 3, 8-11, 14 and 15 were found to be 
completely stable in the buffer solutions at pH 5.0 and 7.4 up to 24 h (data not shown). Only at pH 
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1.2, the compounds suffer from the breakage of the glycosidic bond with half-lifes around 5 h 
(Figure S1 in Supplementary data). Interestingly the two pyridyl derivatives 14 and 15 showed a 
higher stability with larger half-lifes (between 10 and 15 h).  
 
2.3 Biological evaluation 
The synthesized compounds 3, 8-11, 14 and 15 were evaluated for their inhibitory activity against a 
wide variety of DNA and RNA viruses (including, among others, herpes simplex virus type 1, 
herpes simplex virus type 2, vaccinia virus, vesicular stomatitis virus, cytomegalovirus, human 
immunodeficiency virus and influenza virus). Compound 9 could not be tested due to solubility 
problems. Unfortunately, no significant antiviral activity was observed at 100 μM. It should be 
mentioned that no cytotoxicity was detected against the host cell lines (i.e. CEM, HEL, HeLa, Vero 
and MDCK) at concentrations up to 100 μM suggesting that the compounds are free of any toxic 
contaminant. 
Compounds 3, 8-11, 14 and 15 were also evaluated against purine nucleoside phosphorylase of 
Plasmodium falciparum (PfPNP). This enzyme, that preferentially uses inosine as substrate, has a 
central role in purine salvage for the parasite and is a promising validated target for antimalarial 
intervention [12, 14]. Immucillins have been deeply investigated as transition state analogues 
inhibiting PfPNP and compounds such as 5′-methylthio-immucillin-H kills P. falciparum in culture 
[22]. More recently, another immucillin, DADMe-Immucillin-G, has been shown to kill the parasite 
in a primate animal model [14]. When tested against PfPNP using inosine as the natural substrate, 
compounds 8, 10 and 11 showed significant inhibitory activity against this enzyme in the low μM 
range (Ki = 8.1, 3.7 and 5.3 μM, respectively), with values quite comparable to the Km for the 
natural substrate inosine (Km = 5.9 μM) (Table 1). Compounds 8, 10 and 11 were also investigated 
as potential inhibitors or substrates against human and prokaryotic (i.e. E. coli, Mycoplasma 
hyorhinis) PNP. When the compounds were evaluated as potential inhibitors of the conversion of 
100 µM inosine to hypoxanthine, no signs of direct inhibitory activity were observed for both 
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enzymes. Also, no substrate activity was found under conditions where 100 µM inosine was 
converted to hypoxanthine by 96-98% within 1 hour. These findings point to a significant degree of 
selectivity of these compounds as specific anti-PfPNP agents. Unfortunately the compounds were 
devoid of significant inhibitory activity of growth of intraerythrocytic forms of the Plasmodium 
falciparum chloroquine-sensitive strain 3D7 when tested at 25 µM, while chloroquine in the same 
assay gave an IC50 value of 5 nM. The lack of cellular activity may be due to inefficient uptake by 
the erythrocytes and/or the parasites in addition to limited intracellular efficacy. Specific uptake 
studies might provide more insights on this issue. 
 
3. Conclusions 
A number of 8-aryl and pyridyl-substituted inosines have been synthesized making use of the 
recently reported direct arylation reaction mediated by Pd-Cu complexes. Special attention has been 
paid to the removal of metal contaminants that has been accomplished including an extensive 
Quadrasil MP treatment. The 8-substituted inosines obtained proved to be stable at pH values of 7.4 
and 5.0, while at pH=1.2 their half-lives varied between 5 and 10 h. Concerning the biological 
evaluation, no significant toxicity was detected in different types of cell cultures supporting the 
absence of metal-contaminants. Moreover compounds 8, 10 and 11 were able to inhibit P. 
falciparum PNP at low micromolar Ki values similar to that of the Km of inosine. The lack of  
inhibitory or substrate properties of these inosine derivatives 8 against human and prokaryotic PNP 
let us conclude that these 8-arylinosines are highly selective inhibitors of PfPNP and therefore 
represent interesting starting points for further development of specific inhibitors of the enzyme. 
 
 
4. Experimental 
4.1 Synthesis. 
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Melting points were obtained on a Reichert-Jung Kofler apparatus and are uncorrected. The 
elemental analysis was performed with a Heraeus CHN-O-RAPID instrument. The elemental 
compositions of the compounds fell within ± 0.4% of the calculated values. Electrospray mass 
spectra were measured on a quadrupole mass spectrometer equipped with an electrospray source 
(Hewlett-Packard, LC/MS HP 1100). 1H and 13C NMR spectra were recorded on a Varian INNOVA 
300 operating at 299 MHz (1H) and 75 MHz (13C), respectively, and Varian INNOVA-400 
operating at 399 MHZ (1H) and 99 MHz (13C), respectively.  
Analytical TLC was performed on silica gel 60 F254 (Merck) precoated plates (0.2 mm). Spots were 
detected under UV light (254 nm) and/or charring with ninhydrin. Separations on silica gel were 
performed by preparative centrifugal circular thin-layer chromatography (CCTLC) on a 
ChromatotronR (Kiesegel 60 PF254 gipshaltig (Merck)), with layer thickness of 1 and 2 mm and 
flow rate of 4 or 8 mL/min, respectively. Flash column chromatography was performed in a Biotage 
Horizon instrument. 
Microwave reactions were performed using the Biotage Initiator 2.0 single-mode cavity instrument 
from Biotage (Uppsala). Experiments were carried out in sealed microwave process vials utilizing 
the standard absorbance level (400 W maximum power). The temperature was measured with an IR 
sensor on the outside of the reaction vessel. 
High-performance liquid chomatography (HPLC) analysis was performed using an Aligent 
Technologies 1120 Compact LC and an ACE5 C18-300 column (150x4.6 mm, 300Å). UV 
absorption was monitored at diode array.  
4.1.1. 2’,3’-O-Isopropylidene-8-(4’’-methoxyphenyl)inosine (2). To a microwave vial containing 
oven-dried 2´,3´-O-isopropilideneinosine (1) (200 mg, 0.65 mmol) and Cs2CO3 (528 mg, 1.62 
mmol),  CuI (371 mg, 1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) and 4-iodoanisole (304 mg, 1.30 
mmol) in dry DMF (5 mL) were added. The vial was sealed and deoxygenated. Then dried and 
deoxygenated piperidine (26 µL, 0.26 mmol) was added. The mixture was microwaved irradiated at 
120 ºC for 1h. The reaction mixture was diluted with 150 mL of dichloromethane:methanol (1:1) 
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and filtered. The filtrate was evaporated to dryness and the residue obtained was purified by flash 
chromatography (dichloromethane:methanol, 10:1). The purified solid was solved in DMF, treated 
with Quadrasil MP overnight, filtered and coevaporated with diethyl ether to yield 140 mg (52%) of 
2 as a white amorphous solid. EM (ES, positive mode):  m/z  415 (M+H)+.1H NMR (400 MHz, 
DMSO-d6): δ 1.27, 1.44 (s, 6H, C(CH3)2), 3.57 (m, 2H, H-5´), 3.84 (s, 3H, OCH3), 4.13 (m, 1H, H-
4´), 5.02 (m, 2H, H-3´, OH), 5.51 (dd, J = 5.9, 2.2 Hz, 1H, H-2´), 5.86 (d, J = 2.1 Hz, 1H, H-1´), 
7.16 (d, J = 8.6 Hz, 2H, H-3´´), 7.65 (d, J = 8.5 Hz, 2H, H-2´´), 8.11 (s, 1H, H-2), 12.52 (s, 1H, 
NH). 13C NMR (100 MHz, DMSO-d6): δ 25.2, 27.1 (C(CH3)2), 55.4 (OCH3), 61.6 (C-5´), 81.7 (C-
3´), 82.4 (C-2´), 87.2 (C-4´), 90.1 (C-1´), 113.2 (C(CH3)2), 114.4 (C-2´´), 121.1 (C-1´´), 124.4 (C-
5), 130.9 (C-3´´), 145.6 (C-2), 148.4 (C-4), 149.6 (C-8), 156.4 (C-6), 160.8 (C-4´´). Anal. Calc. for 
C20H22N4O6 (%): C, 57.97; H, 5.35; N, 13.52. Found: C, 57.69; H, 5.64; N, 13.49. 
4.1.2. 8-(4’’-Methoxyphenyl)inosine (3). A solution of 2 (100 mg, 0.24 mmol) in a mixture of 
TFA/H2O/dioxano (3:1:1) (2.4 ml) was stirred at rt for 15 min. The reaction was quenched by 
addition of a saturated solution of NH4HCO3 and extracted with EtOAc (3 x 15 ml). The organic 
extracts were dried on anhydrous MgSO4, filtered and evaporated. The residue was purified by 
CCTLC using as eluent dichloromethane/methanol (10:1 to 5:1) to yield 88 mg (98%) of 3 as a 
white solid. Mp: 136-137 ºC. EM (ES, positive mode): m/z 375 (M+H)+. 1H NMR (400 MHz, 
DMSO-d6): δ 3.53, 3.67 (m, 2H, H-5´), 3.84 (s, 3H, OCH3), 3.90 (m, 1H, H-4´), 4.14 (dd, J = 2.1, 
4.8 Hz, 1H, H-3´), 5.10 (dd, J = 6.0, 6.0 Hz, 1H, H-2´), 5.11 (br s, 2H, OH), 5.47 (br s, 1H, OH), 
5.72 (d, J = 6.8 Hz, 1H, H-1´), 7.12 (d, J = 8.7 Hz, 2H, H-3´´), 7.65 (d, J = 8.7 Hz, 2H, H-2´´), 8.06 
(s, 1H, H-2); 13C NMR (100 MHz, DMSO-d6): δ 56.0 (OCH3), 62.8 (C-5´), 71.5 (C-3´), 71.9 (C-2´), 
87.0 (C-4´), 89.9 (C-1´), 114.9 (C-3´´), 122.4 (C-1´´), 125.2 (C-5), 131.6 (C-2´´), 147.9 (C-2), 149.9 
(C-4), 150.6 (C-8), 158.3 (C-6), 161.2 (C-4´´). Anal. Calc. for C17H18N4O6 (%): C, 54.54; H, 4.85; 
N, 14.97. Found: C, 54.36; H, 5.08; N, 14.69. 
4.1.3. 2’,3’-O-Isopropylidene-8-(3’’-methoxyphenyl)inosine (4). Following the conditions described 
for the synthesis of compound 2, 2’,3’-O-isopropylideninosine (1) (200 mg, 0.65 mmol) reacted 
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with 3-iodoanisole (152 µl, 1.30 mmol) in the presence Cs2CO3 (528 mg, 1.62 mmol), CuI (371 mg, 
1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) and piperidine (26 µl, 0.26 mmol) in anhydrous DMF 
(3.2 ml). After work-up, chromatography purification and Quadrasil® MP treatment as described for 
2, 148 mg (55%) of 4 were obtained as a white amorphous solid. MS (ES, positive mode): m/z 415 
(M+H)+. 1H NMR (400 MHz, DMSO-d6): δ 1.19, 1.41 (s, 6H, C(CH3)2), 3.56 (m, 2H, H-5´), 3.81 
(s, 3H, OCH3), 4.09 (m, 1H, H-4´), 4.98 (m, 2H, H-3´, OH), 5.50 (dd, J = 6.2, 2.8 Hz, 1H, H-2´), 
5.86 (d, J = 2.6 Hz, 1H, H-1´), 7.22  (m, 3H, H-4´´, H-5´´, H-6´´), 7.49 (t, J = 7.9 Hz, 1H, H-2´´), 
8.09 (s, 1H, H-2), 12.53 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 25.2, 27.0 (C(CH3)2), 55.3 
(OCH3), 61.5 (C-5´), 81.6 (C-3´), 82.5 (C-2´), 87.2 (C-4´), 90.1 (C-1´), 113.3 (C(CH3)2), 114.8, 
116.0, 121.4 (C-4´´, C-5´´, C-6´´), 124.5 (C-5), 130.0 (C-2´´), 130.1 (C-1´´), 145.9 (C-2), 148.5 (C-
4), 149.4 (C-8), 156.4 (C-6), 159.3 (C-3´´). Anal. Calc. for C20H22N4O6 (%): C, 57.97; H, 5.35; N, 
13.52. Found: C, 57.71; H, 5.44; N, 13.39. 
4.1.4. 2’,3’-O-Isopropylidene-8-(4’’-toly)inosine (5). Following the conditions described for the 
synthesis of compound 2, 2’,3’-O-isopropylideninosine (1) (200 mg, 0.65 mmol) reacted under 
microwave conditions in anhydrous DMF  (3.2 ml) with 4-iodotoluene (284 mg, 1.30 mmol) in the 
presence of Cs2CO3 (528 mg, 1.62 mmol), CuI (371 mg, 1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) 
and piperidine (26 µl, 0.26 mmol). After work-up, chromatography purification and Quadrasil® MP 
treatment as described for 2, 158 mg (61%) of 5 were obtained as a white amorphous solid. MS 
(ES, positive mode): m/z 399 (M+H)+. 1H NMR (400 MHz, DMSO-d6): δ 1.27, 1.43 (s, 6H, 
C(CH3)2), 2.40 (s, 3H, CH3), 3.57 (m, 2H, H-5´), 4.12 (m, 1H, H-4´), 5.01 (m, 2H, H-3´, OH), 5.51 
(dd, J = 6.2, 2.7 Hz, 1H, H-2´), 5.86 (d, J = 2.7 Hz, 1H, H-1´), 7.41 (d, J = 7.9 Hz, 2H, H-3´´), 7.59 
(d, J = 8.0 Hz, 2H, H-2´´), 8.12 (s, 1H, H-2), 12.52 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 
21.7 (CH3), 25.9, 27.7 (C(CH3)2), 62.2 (C-5´), 82.3 (C-3´), 83.1 (C-2´), 87.8 (C-4´), 90.8 (C-1´), 
113.9 (C(CH3)2), 125.2 (C-5), 126.7 (C-1´´), 130.0 (C-2´´), 130.2 (C-3´´), 140.8 (C-4´´), 146.4 (C-
2), 149.1 (C-4), 150.4 (C-8), 157.0 (C-6). Anal. Calc. for C20H22N4O5 (%): C, 60.29; H, 5.57; N, 
14.06. Found: C, 60.05; H, 5.68; N, 14.22. 
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4.1.5. 2’,3’-O-Isopropylidene-8-(4’’-trifluoromethylphenyl)inosine (6). Following the conditions 
described for the synthesis of compound 2, 2’,3’-O-isopropylideninosine  (1) (200 mg, 0.65 mmol) 
in dry DMF (3.2 ml) reacted with 4-trifluoromethylphenyl iodide (191 µl, 1.30 mmol) in the 
presence of  Cs2CO3 (528 mg, 1.62 mmol), CuI (371 mg, 1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) 
and piperidine (26 µl, 0.26 mmol).  After work-up, chromatography purification and Quadrasil® MP 
treatment as described for 2, 135 mg (46%) of 6 were obtained as a white amorphous solid. MS 
(ES, positive mode): m/z 453 (M+H)+, 475 (M+Na)+. 1H NMR (400 MHz, DMSO-d6): δ 1.27, 1.43 
(s, 6H, C(CH3)2), 3.56 (m, 2H, H-5´), 4.15 (m, 1H, H-4´), 5.30 (m, 2H, H-3´, OH), 5.53 (dd, J = 6.2, 
2.3 Hz, 1H, H-2´), 5.87 (d, J = 2.3 Hz, 1H, H-1´), 7.97 (m, 4H, H-2´´, H-3´´), 8.17 (s, 1H, H-2), 
12.60 (br s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 25.8, 27.6 (C(CH3)2), 62.2 (C-5´), 82.3 
(C-3´), 83.3 (C-2´), 88.2 (C-4´), 90.8 (C-1´), 113.9 (C(CH3)2), 124.6 (q ap, J = 272.2 Hz, CF3), 
125.4 (C-5), 126.6 (d, J = 3.1 Hz, C-3´´), 130.9 (d, J = 31.9 Hz, C-4´´), 130.9 (C-2´´), 133.6 (C-1´´), 
146.7 (C-2), 148.8, 149.3  (C-8, C-4), 157.0 (C-6). Anal. Calc. for C20H19F3N4O5 (%): C, 53.10; H, 
4.23; N, 12.38. Found: C, 53.00; H, 4.35; N, 12.42. 
4.1.7. 2’,3’-O-Isopropylidene-8-(3’’-trifluoromethylphenyl)inosine (7). Following the conditions 
described for the synthesis of compound 2, 2’,3’-O-isopropylideninosine  (1) (200 mg, 0.65 mmol) 
in dry DMF (3.2 ml) reacted with 3-trifluoromethylphenyl iodide (187 µl, 1.30 mmol) in the 
presence of Cs2CO3 (528 mg, 1.62 mmol), CuI (371 mg, 1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) 
and piperidine (26 µl, 0.26 mmol). After work-up, chromatography purification and Quadrasil® MP 
treatment as described for 2, 162 mg (55%) of 7 were obtained as a white amorphous solid. MS 
(ES, positive mode): m/z 453 (M+1)+, 475 (M+Na)+. 1H NMR (400 MHz, DMSO-d6): δ 1.26, 1.40 
(s, 6H, C(CH3)2), 3.52  (m, 2H, H-5´), 4.12 (m, 1H, H-4´), 4.99 (m, 2H, H-3´, OH), 5.53 (dd, J = 
6.3, 2.6 Hz, 1H, H-2´), 5.82 (d, J = 2.6 Hz, 1H, H-1´), 7.83 (t, J = 8.0 Hz, 1H, H-5´´), 7.95 (d, J = 
7.9 Hz, 1H, H-4´´), 8.00  (m, 2H, H-2´´, H-6´´), 8.14 (s, 1H, H-2), 12.57 (br s, 1H, NH). 13C NMR 
(100 MHz, DMSO-d6): δ 25.8, 27.6 (C(CH3)2), 62.1 (C-5´), 82.3 (C-3´), 83.1 (C-2´), 88.1 (C-4´), 
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91.0 (C-1´), 113.9 (C(CH3)2), 124.5 (q ap, J = 272.7 Hz, CF3), 125.3 (C-5), 126.7 (d, J = 4.3 Hz, C-
2´´),  127.6 (d, J = 4.1 Hz, C-4´´), 130.3 (d, J = 32.4 Hz, C-3´´), 130.7 (C-1´´), 130.9 (C-5´´), 133.9 
(C-6´´), 146.8 (C-2), 148.9 (C-4), 149.3 (C-8), 157.0 (C-6). Anal. Calc. for C20H19F3N4O5 (%): C, 
53.10; H, 4.23; N, 12.38. Found: C, 52.95; H, 4.41; N, 12.35. 
4.1.8. 8-(3’’-Methoxyphenyl)inosine (8). Following the conditions described for the synthesis of 
compound 3, compound 4 (100 mg, 0.24 mmol) was treated a mixture of TFA/H2O/dioxane (3:1:1) 
(2.4 mL) at rt for 15 min. The reaction was quenched by addition of a saturated solution of 
NH4HCO3. After work-up and CCTLC purification, 76 mg (85%) of 8 were obtained as a white 
solid. Mp: 205-207 ºC. MS (ES, positive mode): m/z 375 (M+H)+. 1H NMR (400 MHz, DMSO-d6): 
δ 3.54, 3.67 (m, 2H, H-5´), 3.83 (s, 3H, OCH3), 3.88 (m, 1H, H-4´), 4.15 (m, 1H, H-3´), 5.03 (s, 1H, 
OH), 5.10 (m, 1H, H-2´), 5.15 (s, 1H, OH), 5.47 (s, 1H, OH), 5.76 (d, J = 6.7 Hz, 1H, H-1´), 7.15 
(d, J = 8.3 Hz, 1H, H-4´´), 7.29 (m, 2H, H-2´´, H-6´´), 7.49 (t, J = 7.9 Hz, 1H, H-5´´), 8.12 (s, 1H, 
H-2), 12.35 (br s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 55.6 (OCH3), 62.4 (C-5´), 71.1 (C-
3´), 71.7 (C-2´), 86.6 (C-4´), 89.7 (C-1´), 115.2 (C-2´´), 116.4 (C-4´´), 122.1 (C-6´´), 125.2 (C-5), 
130.5 (C-5´´), 130.8 (C-1´´), 146.0 (C-2), 149.4 (C-4), 150.7 (C-8), 156.8 (C-6), 159.7 (C-3´´). 
Anal. Calc. for (C17H18N4O6) (%): C, 54.54; H, 4.85; N, 14.97. Found: C, 54.36; H, 5.08; N, 14.69. 
4.1.9. 8-(4’’-Methylphenyl)inosine (9). Following the conditions described for the synthesis of 
compound 3, compound 5 (100 mg, 0.25 mmol) was treated a mixture of TFA/H2O/dioxane (3:1:1) 
(2.5 mL) at rt for 15 min,  and quenched by addition of a saturated solution of NH4HCO3. After 
work-up and CCTLC purification, 78 mg (87%) of 9 were obtained as a white solid. Mp: 296-297 
ºC. MS (ES, positive mode): m/z 359 (M+H)+. 1H NMR (400 MHz, DMSO-d6): δ 2.39 (s, 3H, 
CH3), 3.60 (m, 2H, H-5´), 3.87 (m, 1H, H-4´), 4.13 (m, 1H, H-3´), 5.07 (m, 3H, H-2´, 2 OH), 5.44 
(s, 1H, OH), 5.71 (d, J = 6.8 Hz, 1H, H-1´), 7.38 (d, J = 7.4 Hz, 2H, H-3´´), 7.60 (d, J = 7.5 Hz, 2H, 
H-2´´), 8.10 (s, 1H, H-2), 12.08 (br s, 1H, NH); (1H NMR values are in agreement with those 
partially previously described [23]). 13C NMR (100 MHz, DMSO-d6): δ 21.7 (CH3), 62.7 (C-5´), 
71.3 (C-3´), 71.8 (C-2´), 86.8 (C-4´), 90.0 (C-1´), 125.4 (C-5), 127.1 (C-1´´), 130.0, 130.1 (C-2´´, 
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C-3´´), 140.6 (C-4´´), 146.2 (C-2), 149.6 (C-4), 151.2 (C-8), 157.3 (C-6). Anal. Calc for 
C17H18N4O5 (%): C, 56.98; H, 5.06; N, 15.63. Found: C, 56.75; H, 5.35; N, 15.49. 
4.1.10. 8-(4’’-Trifluoromethylphenyl)inosine (10). Following the conditions described for the 
synthesis of compound 3, compound 6 (100 mg, 0.22 mmol) was treated a mixture of 
TFA/H2O/dioxane (3:1:1) (2.2 mL) at rt for 15 min and quenched by addition of a saturated solution 
of NH4HCO3. After work-up and CCTLC purification, 64 mg (70%) of 10 were obtained as a white 
solid. Mp >170 ºC (decomp). MS (ES, positive mode): m/z 413 (M+H)+. 1H NMR (500 MHz, 
DMSO-d6): δ 3.54, 367 (m, 2H, H-5´), 3.91 (dd, J = 7.4, 4.6 Hz, 1H, H-4´), 4.14 (m, 1H, H-3´), 
5.08 (m, 2H, H-2´, OH), 5.19 (s, 1H, OH), 5.46 (s, 1H, OH), 5.70 (d, J = 6.8 Hz, 1H, H-1´), 7.95 (s, 
4H, H-2´´, H-3´´), 8.14 (s, 1H, H-2). 13C NMR (125 MHz, DMSO-d6): δ 62.3 (C-5´), 71.0 (C-3´), 
71.7 (C-2´), 86.9 (C-4´), 89.8 (C-1´), 124.4 (q ap, J = 272.4 Hz, CF3), 125.4 (C-5), 126.6 (d, J = 4.1 
Hz, C-3´´), 130.6 (d, J = 32.1 Hz, C-4´´), 130.8 (C-2´´), 133.7 (C-1´´), 146.7 (C-2), 149.3 (C-4), 
149.6 (C-8), 157.2 (C-6). Anal. Calc for C17H15F3N4O5 (%): C, 49.52; H, 3.67; N, 13.59. Found: C, 
49.31; H, 3.88; N, 13.70. 
4.1.11. 8-(3’’-Trifluoromethylphenyl)inosine (11). Following the conditions described for the 
synthesis of compound 3, compound 7 (100 mg, 0.22 mmol) was treated a mixture of 
TFA/H2O/dioxane (3:1:1) (2.2 mL) at rt for 15 min and quenched by addition of a saturated solution 
of NH4HCO3. After work-up and CCTLC purification, 55 mg (60%) of 11 were obtained as a white 
solid. Mp: 194-195 ºC. MS (ES, positive mode): m/z 413 (M+H)+. 1H NMR (500 MHz, DMSO-d6): 
δ 3.54, 3.66 (m, 2H, H-5´), 3.90 (dd, J = 7.6, 4.7 Hz, 1H, H-4´), 4.14 (dd, J = 7.6, 4.8 Hz, 1H, H-
3´), 5.06 (m, 2H, H-2´, OH), 5.17 (d, J =4.8 Hz, 1H, OH), 5.48 (d, J = 6.2 Hz, 1H, OH), 5.69 (d, J = 
6.7 Hz, 1H, H-1´), 7.84 (t, J = 7.8 Hz, 1H, H-5´´), 7.97 (d, J = 7.8 Hz, 1H, H-4´´),  8.05 (m, 2H, H-
2´´, H-6´´), 8.16 (s, 1H, H-2). 13C NMR (125 MHz, DMSO-d6): δ 61.9 (C-5´), 70.5 (C-3´), 71.2 (C-
2´), 86.3 (C-4´), 89.3 (C-1´), 123.8 (q ap, J = 272.3 Hz, CF3), 125.0 (C-5), 126.5 (d, J = 4.5 Hz, C-
2´´), 126.8 (d, J = 4.5 Hz, C-4´´), 130.1 (d, J = 32.1 Hz, C-3´´), 130.2, 130.3 (C-5´´, C-1´´), 133.3 
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(C-6´´), 146.0 (C-2), 148.9 (C-8), 149.1 (C-4), 156.4 (C-6). Anal. Calc for C17H15F3N4O5 (%): C, 
49.52; H, 3.67; N, 13.59. Found: C, 49.25; H, 3.90; N, 13.42. 
4.1.12 2’,3’-O-Isopropylidene-8-(4’’-pyridyl)inosine (12). Following the conditions described for 
the synthesis of compound 2, 2’,3’-O-isopropylideninosine  (1) (200 mg, 0.65 mmol) in dry DMF 
(3.2 ml) reacted with 4-iodopyridine (266 mg, 1.30 mmol) in the presence of Cs2CO3 (528 mg, 1.62 
mmol), CuI (371 mg, 1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) and piperidine (26 µl, 0.26 mmol) 
in the microwave at 120 °C for 1 h. The reaction was diluted with CHCl3:MeOH (1:1) (150 mL) 
and filtered. The filtrate was evaporated to dryness and the residue obtained was purified by flash 
chromatography (dichloromethane:methanol, 10:1). The purified solid was solved in DMF, treated 
with Quadrasil MP overnight, filtered and coevaporated with diethyl ether (2x 5mL) to yield 138 
mg (55%) of 12 as a white amorphous solid. MS (ES, positive mode): m/z 386 (M+H)+. 1H NMR 
(400 MHz, DMSO-d6): δ 1.27, 1.44 (s, 6H, C(CH3)2), 3.55 (m, 2H, H-5´), 4.15 (m, 1H, H-4´), 5.02 
(m, 2H, H-3´, OH), 5.53 (dd, J = 6.3, 2.6 Hz, 1H, H-2´), 5.90 (d, J = 2.5 Hz, 1H, H-1´), 7.74 (m, 
2H, H-2´´), 8.17 (s, 1H, H-2), 8.85 (m, 2H, H-3´´), 12.68 (br s, 1H, NH). 13C NMR (100 MHz, 
DMSO-d6): δ 25.9, 27.7 (C(CH3)2), 62.1 (C-5´), 82.3 (C-3´), 83.2 (C-2´), 88.3 (C-4´), 90.8 (C-1´), 
113.9 (C(CH3)2), 124.2 (C-2´´), 125.5 (C-5), 137.0 (C-1´´), 147.1 (C-2), 147.9 (C-3´´), 149.5 (C-4), 
151.0 (C-8), 157.0 (C-6). Anal. Calc for C18H19N5O5 (%): C, 56.10; H, 4.97; N, 18.17. Found: C, 
55.93; H, 5.13; N, 18.25. 
4.1.13 2’,3’-O-Isopropylidene-8-(3’’-pyridyl)inosine (13). Following the conditions described for 
the synthesis of compound 2, 2’,3’-O-isopropylideninosine  (1) (200 mg, 0.65 mmol) in dry DMF 
(3.3 ml) reacted under MW conditions with 3-iodopyridine (266 mg, 1.30 mmol) in the presence 
Cs2CO3 (528 mg, 1.62 mmol), CuI (371 mg, 1.95 mmol), Pd(OAc)2 (7 mg, 0.03 mmol) and 
piperidine (26 µl, 0.26 mmol). Following the work-up described for the synthesis of 12, compound 
13 was obtained (135 mg, 54%). EM (ES, positive mode): m/z 386 (M+H)+. 1H NMR (500 MHz, 
DMSO-d6): δ 1.27, 1.43 (s, 6H, C(CH3)2), 3.53 (m, 2H, H-5´), 4.13 (dd, J = 9.0, 5.9 Hz, 1H, H-4´), 
5.00 (m, 2H, H-3´, OH), 5.53 (dd, J = 6.2, 2.1 Hz, 1H, H-2´), 5.82 (d, J = 2.0 Hz, 1H, H-1´), 7.79 
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(m, 1H, H-5´´), 8.15 (s, 1H, H-2), 8.17 (m, 1H, H-6´´), 8.81 (m, 1H, H-4´´), 9.29 (s, 1H, H-2´´), 
12.57 (s, 1H, NH). 13C NMR (125 MHz, DMSO-d6): δ 25.6, 27.5 (C(CH3)2), 61.9 (C-5´), 82.1 (C-
3´), 83.0 (C-2´), 87.89 (C-4´), 90.6 (C-1´),113.7 (C(CH3)2), 124.0 (C-5´´), 125.2 (C-5), 126.1 (C-
1´´), 137.0 (C-6´´), 146.6 (C8), 147.9 (C-2), 149.1 (C-4), 150.2 (C-2´´), 151.4 (C-4´´), 156.8 (C-6). 
Anal. Calc for C18H19N5O5 (%): C, 56.10; H, 4.97; N, 18.17. Found: C, 55.99; H, 5.10; N, 18.28. 
4.1.14 8-(4’’-Pyridyl)inosine (14). Following the conditions described for the synthesis of 
compound 3, compound 12 (100 mg, 0.26 mmol) was treated a mixture of TFA/H2O/dioxane 
(3:1:1) (2.6 mL) at rt for 15 min and quenched by addition of a saturated solution of NH4HCO3. 
After work-up and CCTLC purification, 63 mg (78%) of 14 were obtained as a white solid. Mp > 
200 ºC (decomp). MS (ES, positive mode): m/z 346 (M+H)+. 1H NMR (400 MHz, DMSO-d6): δ 
3.55, 3.68 (m, 2H, H-5´), 3.92 (dd, J =7.4, 4.4 Hz, 1H, H-4´), 4.15 (m, 1H, H-3´), 4.95 (dd, J =5.1, 
5.1 Hz, 1H, OH), 5.05 (dd, J = 6.0, 6.0 Hz, 1H, H-2´), 5.11 (d, J = 4.8 Hz, 1H, OH), 5.40 (d, J = 6.3 
Hz, 1H, OH), 5.74 (d, J = 6.6 Hz, 1H, H-1´), 7.73 (d, J = 5.9 Hz, 2H, H-2´´), 8.13 (s 1H, H-2), 8.79 
(d, J = 5.8 Hz, 1H, H-3´´), 12.52 (s, 1H, NH). 13C NMR (100 MHz, DMSO-d6): δ 61.7 (C-5´), 70.3 
(C-3´), 71.2 (C-2´), 86.3 (C-4´), 89.2 (C-1´), 123.4 (C-2´´), 125.0 (C-5), 136.5 (C-1´´), 146.0 (C-2), 
147.8 (C-8), 149.2 (C-4), 150.1 (C-3´´), 156.2 (C-6). Anal. Calc. for C15H15N5O5 (%): C, 52.17; H, 
4.38; N, 20.38. Found: C, 52.03; H, 4.44; N, 20.25. 
4.1.15. 8-(3-Pyridyl)inosine (15). Following the conditions described for the synthesis of compound 
3, compound 13 (100 mg, 0.26 mmol) was treated a mixture of TFA/H2O/dioxane (3:1:1) (2.6 mL) 
at rt for 15 min and it was quenched by addition of a saturated solution of NH4HCO3. After work-up 
and CCTLC purification, 55 mg (69%) of 15 were obtained as a white solid.  Mp > 200 ºC 
(decomp). MS (ES, positive mode): m/z 346 (M+H)+. 1H NMR (500 MHz, DMSO-d6): δ 3.25 (br s, 
2H, 2 OH), 3.53 (dd, J = 11.9, 4.2 Hz, 1H, H-5´), 3.66 (dd, J = 11.9, 4.0 Hz, 1H, H-5´), 3.91 (m, 
1H, H-4´), 4.13 (m, 1H, H-3´), 5.06 (dd, J = 5.9, 5.9 Hz, 1H, H-2´), 5.36 (br s, 1H, OH), 5.68 (d, J = 
6.7 Hz, 1H, H-1´), 7.60 (dd, J = 7.5, 4.9 Hz, 1H, H-5´´), 8.06 (s 1H, H-2), 8.11 (d, J = 7.8 Hz, 1H, 
H-6´´), 8.74 (d, J = 3.6 Hz, 1H, H-4´´), 8.89 (s, 1H, H-2´´). 13C NMR (125 MHz, DMSO-d6): δ 62.5 
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(C-5´), 71.2 (C-3´), 71.9 (C-2´), 87.0 (C-4´), 89.8 (C-1´), 124.1 (C-5´´), 125.5 (C-5), 126.3 (C-1´´), 
137.4 (C-6´´), 147.5, 147.7 (C-8, C-2), 149.7 (C-4), 150.1 (C-2´´), 151.1 (C-4´´), 158.8 (C-6). Anal 
Calc for C15H15N5O5 (%): C, 52.17; H, 4.38; N, 20.28. Found: C, 52.10; H, 4.42; N, 20.31. 
4.2. Hydrolytic stability studies. Solutions were prepared using 10 µL of a 5 mM stock solution of 
each compound in DMSO and 990 µL of phosphate buffer (pH 7.4) or citrate buffer (pH 5.0) or 
trifluoroacetate buffer (pH 1.2) to obtain a final concentration of 50 µM. The samples were 
incubated at 37 ºC. Aliquots were taken at different time points (t = 0, 0.5, 1, 4 and 24 h) and 
analyzed by HPLC. Injection volume: 20 µL. Flow rate: 1.0 mL/min. Bottle A: Acetonitrile; bottle 
B. water containing 0.05% trifluoroacetic acid. Gradient employed: 10% of bottle A to 100% bottle 
A in 20 min.  
4.3. Biological assays  
4.3.1. Antiviral assays. The compounds were evaluated against the following viruses: herpes 
simplex virus type 1 (HSV-1) strain KOS, thymidine kinase-deficient (TK−) HSV-1 KOS strain 
resistant to ACV (ACVr), herpes simplex virus type 2 (HSV-2) strains Lyons and G, vaccinia virus 
Lederle strain, respiratory syncytial virus (RSV) strain Long, vesicular stomatitis virus (VSV), 
Coxsackie B4, Parainfluenza 3, Influenza virus A (subtypes H1N1, H3N2), influenza virus B, 
Reovirus-1, Sindbis and Punta Toro. The antiviral assays were based on inhibition of virus-induced 
cytopathicity in human embryonic lung (HEL) fibroblasts, African green monkey cells (Vero), 
human epithelial cervix carcinoma cells (HeLa) or Madin-Darby canine kidney cells (MDCK). 
Confluent cell cultures in microtiter 96-well plates were inoculated with 100 CCID50 of virus (1 
CCID50 being the virus dose to infect 50% of the cell cultures) in the presence of varying 
concentrations of the test compounds. Viral cytopathicity was recorded as soon as it reached 
completion in the control virus-infected cell cultures that were not treated with the test compounds. 
Antiviral activity was expressed as the EC50 or compound concentration required to reduce virus-
induced cytopathicity by 50%. 
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4.3.2. Human and prokaryotic PNP assays. The separation of inosine from hypoxanthine was 
performed by HPLC on a reverse phase column RP-18 (Merck, Darmstadt, Germany) using a linear 
gradient [from 100 % buffer A (50 mM NaH2PO4 (Acros Organics, Geel, Belgium) and 5 mM 
heptane sulfonic acid; pH 3.2) to 75 % buffer A and 25 % acetonitrile] as follows: 10 min linear 
gradient of 100 % buffer A to 98 % buffer A + 2 % acetonitrile; 10 min linear gradient to 90 % 
buffer A + 10% acetonitrile; 5 min linear gradient to 75 % buffer A + 25 % acetonitrile; 5 min 
linear gradient to 100 % buffer A followed by equilibration at 100 % buffer A for 10 min.  
To study the phosphorolysis of the different compounds and inosine by PNPHyor, PNPEcoli and 
human PNP (ProSpec, Rehovot, Israel) the compounds (100 µM) were exposed to the enzyme (20 
nM PNPHyor and PNPEcoli or 6 nM human PNP) and incubated at 37 °C in PNP buffer (50 mM 
MOPS; 0.2 mM EDTA; 200 mM potassium phosphate; pH = 6.5) in a total volume of 500 µL. 
After 60 min, a 100 µL-fraction was withdrawn and subjected to HPLC analysis. For analysis of the 
inhibitory activity of the test compounds against PNP-catalysed hydrolysis of 100 µM inosine, the 
test compounds were added to PNP at 250 µM and hydrolysis of inosine to hypoxanthine was 
measured after 60 min incubation by the above-described HPLC analysis. 
4.3.3. PfPNP inhibition assays. The coding sequence of PfPNP was previously cloned in pET28a 
and expression was performed in E. coli BL21 (DE3) cells, by induction with 1 mM IPTG at 37 ºC 
for 4 h. The purification was performed as previously described.[13] To monitor the reaction, the 
activity of the enzyme was coupled to the xanthine oxidase, that catalyze the oxidation of 
hypoxanthine to uric acid, whose appearance can be followed at 293nm (molar extinction 
coefficient for uric acid: 12.9 mM-1 cm-1). The reaction mixture to determine the activity contained 
50 mM KH2PO4, pH 7.5, 60 mU xanthine oxidase, 25 nM (0.73 μg) PfPNP, and 25 μM inosine at 
25 ºC in a final volume of 1 ml.  For inhibition studies, the reaction rates were measured with 
variable inhibitor concentrations and inosine as substrate (25 μM) and at least five concentrations 
were tested.  
Supplementary data.  
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Supplementary data associated with this article can be found in the online version. These data 
include MOL files, 1H and 13C NMR spectra of the most important compounds described in this 
article, and percentage of intact nucleosides in the function of time at pH=1.2. 
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Figure 1. Proposed 8-arylinosines 
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Scheme 1. Reagents and conditions: (a) 4-Iodoanisole; Cs2CO3, Pd(OAc)2, CuI, piperidine; DMF; 
80 ºC, 16 h (22% yield); (b) 4-Iodoanisole; Cs2CO3, Pd(OAc)2, CuI, piperidine; DMF;  MW 120 ºC, 
1 h (52% yield);  (c) TFA 60%, H2O:1,4-dioxane, 15 min, and then quenching with NH4HCO3 
(98% yield). 
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Scheme 2. Reagents and conditions: (a) Ar-I; Cs2CO3, Pd(OAc)2, CuI, piperidine; DMF;  MW 120 
ºC, 1h (46-61%); (b) TFA 60%, H2O: 1,4-dioxane, 15 min, and then quenching with NH4HCO3 (60-
87% yield) 
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Scheme 3. Reagents and conditions: (a) 4-iodo- or 3-iodopyridine, Cs2CO3, Pd(OAc)2, CuI, 
piperidine; DMF;  MW 120 ºC; 1 h (12: 55%; 13: 54%); (b) TFA 60%, H2O: 1,4-dioxane, 15 min, 
and then quenching with NH4HCO3 (14: 78%; 15: 69%yield) 
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Table 1 
Inhibition of P. falciparum PNP by compounds 3, 8-11, 14 and 15. 
 
Compound  PfPNP Ki (μM) 
3 - a 
8 8.1 
9 - b 
10 3.69 
11 5.33 
14 >80 
15 - a 
 
a No inhibition at 200 μM for PfPNP. b Poor solubility 
 
